Contrasting Veracyte (NASDAQ:VCYT) and Connect Biopharma (NASDAQ:CNTB)

Veracyte (NASDAQ:VCYT) and Connect Biopharma (NASDAQ:CNTB) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Risk and Volatility

Veracyte has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500.

Valuation & Earnings

This table compares Veracyte and Connect Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15 million	6.81	$66.35 million	$1.41	31.08
Connect Biopharma	$60,000.00	1,122.97	-$55.48 million	($1.19)	-0.90

Veracyte has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Veracyte and Connect Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Connect Biopharma	N/A	-165.41%	-121.58%

Institutional & Insider Ownership

58.7% of Connect Biopharma shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Veracyte and Connect Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	2	6	2	2.82
Connect Biopharma	1	0	7	0	2.75

Veracyte presently has a consensus price target of $55.78, indicating a potential upside of 27.29%. Connect Biopharma has a consensus price target of $6.86, indicating a potential upside of 540.85%. Given Connect Biopharma’s higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Veracyte.

Summary

Veracyte beats Connect Biopharma on 10 of the 15 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.